| Stem definition | Drug id | CAS RN |
|---|---|---|
| hypnotics, barbituric acid derivatives | 2095 | 76-74-4 |
| Dose | Unit | Route |
|---|---|---|
| 0.10 | g | O |
| 0.10 | g | P |
| 0.10 | g | R |
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 12.61 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 80 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.91 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 0.47 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.39 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 22 hours | Lombardo F, Berellini G, Obach RS |
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 19, 1973 | FDA | OAK PHARMS |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Propofol infusion syndrome | 200.74 | 102.46 | 31 | 1120 | 952 | 63486919 |
| Mitochondrial DNA mutation | 169.48 | 102.46 | 24 | 1127 | 398 | 63487473 |
| Drug ineffective for unapproved indication | 162.56 | 102.46 | 48 | 1103 | 34015 | 63453856 |
| Gene mutation | 136.57 | 102.46 | 24 | 1127 | 1641 | 63486230 |
| CSF oligoclonal band present | 130.71 | 102.46 | 19 | 1132 | 381 | 63487490 |
| Multiple-drug resistance | 126.32 | 102.46 | 27 | 1124 | 5143 | 63482728 |
| Status epilepticus | 125.59 | 102.46 | 33 | 1118 | 15200 | 63472671 |
| Blood gases abnormal | 124.85 | 102.46 | 20 | 1131 | 777 | 63487094 |
| Pleocytosis | 116.51 | 102.46 | 19 | 1132 | 826 | 63487045 |
None
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug ineffective for unapproved indication | 220.58 | 95.20 | 67 | 1412 | 51171 | 79691738 |
| Propofol infusion syndrome | 178.21 | 95.20 | 31 | 1448 | 1952 | 79740957 |
| Mitochondrial DNA mutation | 168.26 | 95.20 | 24 | 1455 | 409 | 79742500 |
| Status epilepticus | 134.76 | 95.20 | 39 | 1440 | 25002 | 79717907 |
| Multiple-drug resistance | 132.11 | 95.20 | 31 | 1448 | 8777 | 79734132 |
| CSF oligoclonal band present | 129.27 | 95.20 | 19 | 1460 | 402 | 79742507 |
| Gene mutation | 124.50 | 95.20 | 24 | 1455 | 2662 | 79740247 |
| Blood gases abnormal | 116.51 | 95.20 | 20 | 1459 | 1160 | 79741749 |
| Drug ineffective | 114.58 | 95.20 | 118 | 1361 | 1080795 | 78662114 |
| Pleocytosis | 105.94 | 95.20 | 19 | 1460 | 1420 | 79741489 |
None
| Source | Code | Description |
|---|---|---|
| ATC | N05CA01 | NERVOUS SYSTEM PSYCHOLEPTICS HYPNOTICS AND SEDATIVES Barbiturates, plain |
| MeSH PA | D000759 | Adjuvants, Anesthesia |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D018682 | GABA Agents |
| MeSH PA | D018757 | GABA Modulators |
| MeSH PA | D006993 | Hypnotics and Sedatives |
| MeSH PA | D018377 | Neurotransmitter Agents |
| CHEBI has role | CHEBI:91016 | GABAA receptor agonists |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| General anesthesia | indication | 50697003 | |
| Severe anxiety (panic) | indication | 80583007 | |
| Epilepsy | indication | 84757009 | DOID:1826 |
| Seizure disorder | indication | 128613002 | |
| Insomnia | indication | 193462001 | |
| Status epilepticus | indication | 230456007 | DOID:1824 |
| Cerebral ischemia | indication | 287731003 | |
| Local anesthesia | indication | 386761002 | |
| Tetanus Adjunct Treatment | indication | ||
| Benign intracranial hypertension | off-label use | 68267002 | DOID:11459 |
| Apnea | contraindication | 1023001 | |
| Suicidal thoughts | contraindication | 6471006 | |
| Alcoholism | contraindication | 7200002 | |
| Hyperammonemia | contraindication | 9360008 | |
| Chronic obstructive lung disease | contraindication | 13645005 | DOID:3083 |
| Hepatic encephalopathy | contraindication | 13920009 | DOID:13413 |
| Disorder of lung | contraindication | 19829001 | DOID:850 |
| Depressive disorder | contraindication | 35489007 | |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Hyperactive behavior | contraindication | 44548000 | |
| Low blood pressure | contraindication | 45007003 | |
| Heart disease | contraindication | 56265001 | DOID:114 |
| Hepatic failure | contraindication | 59927004 | |
| Substance abuse | contraindication | 66214007 | |
| Hepatic coma | contraindication | 72836002 | DOID:12550 |
| Sleep apnea | contraindication | 73430006 | DOID:0050847 |
| Decreased respiratory function | contraindication | 80954004 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Pneumonia | contraindication | 233604007 | DOID:552 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Sleep automatism | contraindication | 247962006 | |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Pregnancy, function | contraindication | 289908002 | |
| Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
| Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
| Respiratory insufficiency | contraindication | 409623005 | |
| Porphyria | contraindication | 418470004 | |
| Acute exacerbation of asthma | contraindication | 708038006 |
| Species | Use | Relation |
|---|---|---|
| Cats | General anesthesia | Indication |
| Dogs | General anesthesia | Indication |
| Dogs | Strychnine poisoning | Indication |
| Dogs | Euthanasia | Indication |
| Horses | General anesthesia | Indication |
| Horses | Sedative-relaxant | Indication |
| Product | Applicant | Ingredients |
|---|---|---|
| Somnopentyl Injection | Intervet Inc. | 1 |
| Combuthal Powder | Bimeda Animal Health Limited | 2 |
| Chloropent | Zoetis Inc. | 3 |
| Beuthanasia-D Special | Intervet Inc. | 2 |
| Euthasol | Virbac AH Inc. | 2 |
| Euthanasia-III Solution | Med-Pharmex Inc. | 2 |
| Pentobarbital Sodium and Phenytoin Sodium | Akorn Animal Health Inc. | 2 |
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 7.81 | acidic |
| pKa2 | 9.51 | acidic |
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Gamma-aminobutyric acid receptor subunit beta-3 | Ion channel | POSITIVE ALLOSTERIC MODULATOR | IC50 | 4.06 | CHEMBL | CHEMBL | |||
| GABA-A receptor alpha-1/beta-2/gamma-2 | Ion channel | POSITIVE ALLOSTERIC MODULATOR | EC50 | 4.30 | WOMBAT-PK | CHEMBL | |||
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 2.55 | WOMBAT-PK | |||||
| GABA A receptor alpha-2/beta-2/gamma-2 | Ion channel | EC50 | 4.30 | CHEMBL | |||||
| GABA-A receptor; anion channel | Ion channel | IC50 | 5.77 | CHEMBL |
| ID | Source |
|---|---|
| 4018516 | VUID |
| N0000146838 | NUI |
| D00499 | KEGG_DRUG |
| 24876-35-5 | SECONDARY_CAS_RN |
| 57-33-0 | SECONDARY_CAS_RN |
| 4018036 | VANDF |
| 4018516 | VANDF |
| C0030883 | UMLSCUI |
| CHEBI:7983 | CHEBI |
| RAV | PDB_CHEM_ID |
| CHEMBL448 | ChEMBL_ID |
| DB00312 | DRUGBANK_ID |
| CHEMBL971 | ChEMBL_ID |
| D010424 | MESH_DESCRIPTOR_UI |
| 4737 | PUBCHEM_CID |
| 5480 | IUPHAR_LIGAND_ID |
| 703 | INN_ID |
| I4744080IR | UNII |
| 203085 | RXNORM |
| 2161 | MMSL |
| 3697 | MMSL |
| 5253 | MMSL |
| 5254 | MMSL |
| 71886 | MMSL |
| d00335 | MMSL |
| 001411 | NDDF |
| 001412 | NDDF |
| 33231001 | SNOMEDCT_US |
| 372703009 | SNOMEDCT_US |
| 66843009 | SNOMEDCT_US |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Pentobarbital Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-181 | INJECTION | 50 mg | INTRAMUSCULAR | ANDA | 25 sections |
| Pentobarbital Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-181 | INJECTION | 50 mg | INTRAMUSCULAR | ANDA | 25 sections |
| Pentobarbital Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 17478-181 | INJECTION | 50 mg | INTRAMUSCULAR | ANDA | 25 sections |
| Pentobarbital Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24201-010 | INJECTION, SOLUTION | 50 mg | INTRAMUSCULAR | ANDA | 24 sections |
| Pentobarbital Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24201-010 | INJECTION, SOLUTION | 50 mg | INTRAMUSCULAR | ANDA | 24 sections |
| pentobarbital sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-676 | INJECTION, SOLUTION | 50 mg | INTRAVENOUS | ANDA | 26 sections |
| Nembutal Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 76478-501 | INJECTION | 50 mg | INTRAVENOUS | ANDA | 25 sections |
| Nembutal Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 76478-501 | INJECTION | 50 mg | INTRAVENOUS | ANDA | 25 sections |
| Nembutal Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 76478-501 | INJECTION | 50 mg | INTRAVENOUS | ANDA | 25 sections |